Orally administered MOTS-c analogue ameliorates dextran sulfate sodium-induced colitis by inhibiting inflammation and apoptosis.

Jiang J, Chang X, Nie Y, Xu L, Yang L, Peng Y, Chang M

European journal of pharmacology15 Dec 2022Cited by 21 (Europe PMC)

PMID36528071DOI10.1016/j.ejphar.2022.175469PepBankPUB-36528071

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study15

13 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In animals with DSS-induced colitis, intraperitoneal MOTS‑c reduced body weight loss.
In plain wordsIn animals with induced colitis, MOTS‑c injections reduced weight loss.
Peptide
MOTS-c
Outcome
DecreaseBody weight loss in DSS colitis
Study
n: not reported in source
DSS-induced colitis
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
Dose not stated · intraperitonealAs given in this study.
Source sentences
Summary
The results showed that intraperitoneal (i.p.) administration of MOTS-c significantly ameliorated the symptoms of DSS-induced experimental colitis, such as body weight loss, colon length shortening, diarrhea, and histological damage.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of this study was to investigate the protective effects of MOTS-c against dextran sulfate sodium (DSS)-induced colitis.
Report a problemFND-3652807101
02AnimalAnimal study (in vivo)Efficacy outcome
In animals with DSS-induced colitis, intraperitoneal MOTS‑c reduced colon length shortening.
In plain wordsIn animals with induced colitis, MOTS‑c injections reduced shortening of the colon.
Peptide
MOTS-c
Outcome
DecreaseColon length shortening in DSS colitis
Study
n: not reported in source
DSS-induced colitis
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
Dose not stated · intraperitonealAs given in this study.
Source sentences
Summary
The results showed that intraperitoneal (i.p.) administration of MOTS-c significantly ameliorated the symptoms of DSS-induced experimental colitis, such as body weight loss, colon length shortening, diarrhea, and histological damage.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of this study was to investigate the protective effects of MOTS-c against dextran sulfate sodium (DSS)-induced colitis.
Report a problemFND-3652807102
03AnimalAnimal study (in vivo)Efficacy outcome
In animals with DSS-induced colitis, intraperitoneal MOTS‑c reduced diarrhea.
In plain wordsIn animals with induced colitis, MOTS‑c injections reduced diarrhea.
Peptide
MOTS-c
Outcome
DecreaseDiarrhea in DSS colitis
Study
n: not reported in source
DSS-induced colitis
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
Dose not stated · intraperitonealAs given in this study.
Source sentences
Summary
The results showed that intraperitoneal (i.p.) administration of MOTS-c significantly ameliorated the symptoms of DSS-induced experimental colitis, such as body weight loss, colon length shortening, diarrhea, and histological damage.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of this study was to investigate the protective effects of MOTS-c against dextran sulfate sodium (DSS)-induced colitis.
Report a problemFND-3652807103
04AnimalAnimal study (in vivo)Efficacy outcome
In animals with DSS-induced colitis, intraperitoneal MOTS‑c reduced histological damage.
In plain wordsIn animals with induced colitis, MOTS‑c injections reduced tissue damage seen under the microscope.
Peptide
MOTS-c
Outcome
DecreaseHistological damage in DSS colitis
Study
n: not reported in source
DSS-induced colitis
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
Dose not stated · intraperitonealAs given in this study.
Source sentences
Summary
The results showed that intraperitoneal (i.p.) administration of MOTS-c significantly ameliorated the symptoms of DSS-induced experimental colitis, such as body weight loss, colon length shortening, diarrhea, and histological damage.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of this study was to investigate the protective effects of MOTS-c against dextran sulfate sodium (DSS)-induced colitis.
Report a problemFND-3652807104
05AnimalAnimal study (in vivo)Efficacy outcome
In animals with DSS-induced colitis, MOTS‑c down-regulated the expression of pro-inflammatory cytokines.
In plain wordsIn animals with induced colitis, MOTS‑c lowered the activity of genes for inflammatory signal proteins.
Peptide
MOTS-c
Outcome
DecreasePro-inflammatory cytokine expression
Study
n: not reported in source
DSS-induced colitis
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · intraperitonealAs given in this study.
Source sentences
Summary
MOTS-c down-regulated the expression of pro-inflammatory cytokines
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of this study was to investigate the protective effects of MOTS-c against dextran sulfate sodium (DSS)-induced colitis.
Report a problemFND-3652807105
06AnimalAnimal study (in vivo)Efficacy outcome
In animals with DSS-induced colitis, MOTS‑c decreased plasma myeloperoxidase levels.
In plain wordsIn animals with induced colitis, MOTS‑c lowered blood levels of myeloperoxidase, an inflammation marker.
Peptide
MOTS-c
Outcome
DecreasePlasma myeloperoxidase
Study
n: not reported in source
DSS-induced colitis
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · intraperitonealAs given in this study.
Source sentences
Summary
decreased the plasma levels of myeloperoxidase, and inhibited the activation of macrophages and recruitment of neutrophils.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of this study was to investigate the protective effects of MOTS-c against dextran sulfate sodium (DSS)-induced colitis.
Report a problemFND-3652807106
07AnimalAnimal study (in vivo)Efficacy outcome
In animals with DSS-induced colitis, MOTS‑c inhibited the activation of macrophages.
In plain wordsIn animals with induced colitis, MOTS‑c reduced the activation of macrophages, a type of immune cell.
Peptide
MOTS-c
Outcome
DecreaseMacrophage activation
Study
n: not reported in source
DSS-induced colitis
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · intraperitonealAs given in this study.
Source sentences
Summary
inhibited the activation of macrophages and recruitment of neutrophils.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of this study was to investigate the protective effects of MOTS-c against dextran sulfate sodium (DSS)-induced colitis.
Report a problemFND-3652807107
08AnimalAnimal study (in vivo)Efficacy outcome
In animals with DSS-induced colitis, MOTS‑c inhibited the recruitment of neutrophils.
In plain wordsIn animals with induced colitis, MOTS‑c reduced the arrival of neutrophils, a type of immune cell.
Peptide
MOTS-c
Outcome
DecreaseNeutrophil recruitment
Study
n: not reported in source
DSS-induced colitis
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · intraperitonealAs given in this study.
Source sentences
Summary
inhibited the activation of macrophages and recruitment of neutrophils.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of this study was to investigate the protective effects of MOTS-c against dextran sulfate sodium (DSS)-induced colitis.
Report a problemFND-3652807108
09AnimalAnimal study (in vivo)Mechanism
In animals with DSS-induced colitis, MOTS‑c treatment had anti-apoptotic effects.
In plain wordsIn animals with induced colitis, MOTS‑c reduced programmed cell death.
Peptide
MOTS-c
Outcome
DecreaseApoptosis
Study
n: not reported in source
DSS-induced colitis
Outcome group
Receptor activity and mechanism · Gastrointestinal
Studied dose
Dose not stated · intraperitonealAs given in this study.
Source sentences
Summary
treatment with MOTS-c exhibited anti-apoptotic effects and significantly suppressed the phosphorylation of AMPKα1/2, ERK, and JNK.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of this study was to investigate the protective effects of MOTS-c against dextran sulfate sodium (DSS)-induced colitis.
Report a problemFND-3652807109
10AnimalAnimal study (in vivo)Mechanism
In animals with DSS-induced colitis, MOTS‑c significantly suppressed the phosphorylation of AMPKα1/2.
In plain wordsIn animals with induced colitis, MOTS‑c reduced activation of the AMPK enzyme.
Peptide
MOTS-c
Outcome
DecreaseAMPKα1/2 phosphorylation
Study
n: not reported in source
DSS-induced colitis
Outcome group
Receptor activity and mechanism · Gastrointestinal
Studied dose
Dose not stated · intraperitonealAs given in this study.
Source sentences
Summary
significantly suppressed the phosphorylation of AMPKα1/2, ERK, and JNK.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of this study was to investigate the protective effects of MOTS-c against dextran sulfate sodium (DSS)-induced colitis.
Report a problemFND-3652807110
11AnimalAnimal study (in vivo)Mechanism
In animals with DSS-induced colitis, MOTS‑c significantly suppressed the phosphorylation of ERK.
In plain wordsIn animals with induced colitis, MOTS‑c reduced activation of the ERK enzyme.
Peptide
MOTS-c
Outcome
DecreaseERK phosphorylation
Study
n: not reported in source
DSS-induced colitis
Outcome group
Receptor activity and mechanism · Gastrointestinal
Studied dose
Dose not stated · intraperitonealAs given in this study.
Source sentences
Summary
significantly suppressed the phosphorylation of AMPKα1/2, ERK, and JNK.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of this study was to investigate the protective effects of MOTS-c against dextran sulfate sodium (DSS)-induced colitis.
Report a problemFND-3652807111
12AnimalAnimal study (in vivo)Mechanism
In animals with DSS-induced colitis, MOTS‑c significantly suppressed the phosphorylation of JNK.
In plain wordsIn animals with induced colitis, MOTS‑c reduced activation of the JNK enzyme.
Peptide
MOTS-c
Outcome
DecreaseJNK phosphorylation
Study
n: not reported in source
DSS-induced colitis
Outcome group
Receptor activity and mechanism · Gastrointestinal
Studied dose
Dose not stated · intraperitonealAs given in this study.
Source sentences
Summary
significantly suppressed the phosphorylation of AMPKα1/2, ERK, and JNK.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of this study was to investigate the protective effects of MOTS-c against dextran sulfate sodium (DSS)-induced colitis.
Report a problemFND-3652807112
13AnimalAnimal study (in vivo)Efficacy outcome
In animals with DSS-induced colitis, oral MOTS‑c did not result in any significant improvements.
In plain wordsIn animals with induced colitis, MOTS‑c given by mouth did not clearly improve colitis.
Peptide
MOTS-c
Outcome
No significant changeColitis improvement with oral MOTS-c
Study
n: not reported in source
DSS-induced colitis
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
Dose not stated · oralAs given in this study.
Source sentences
Summary
Notably, oral administration of MOTS-c did not result in any significant improvements.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of this study was to investigate the protective effects of MOTS-c against dextran sulfate sodium (DSS)-induced colitis.
Report a problemFND-3652807113

Studies that did not test the peptide alone2

In this study, MOTS-c was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking MOTS-c.

14AnimalNot a test of MOTS-c aloneAnimal study (in vivo)Efficacy outcome
In animals with DSS-induced colitis, oral administration of the MOTS‑c analogue MP significantly ameliorated colitis.
In plain wordsIn animals with induced colitis, the MOTS‑c analogue MP, given by mouth, clearly reduced colitis.
Peptide
MOTS-c
Outcome
DecreaseDSS colitis with oral MP
Study
n: not reported in source
DSS-induced colitis
Outcome group
Gastrointestinal protection · Gastrointestinal
Source sentences
Summary
in vivo experiments showed that oral administration of MP significantly ameliorated DSS-induced colitis.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of this study was to investigate the protective effects of MOTS-c against dextran sulfate sodium (DSS)-induced colitis.
In this study, MOTS-c was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MOTS-c.
Report a problemFND-3652807115
15LabNot a test of MOTS-c aloneOther designPharmacokinetics
In in vitro experiments, the MOTS‑c analogue MP had a longer half-life than MOTS‑c.
In plain wordsIn lab tests, the MOTS‑c analogue MP lasted longer than MOTS‑c.
Peptide
MOTS-c
Outcome
IncreaseHalf-life of MP versus MOTS-c in vitro
Study
n: not reported in source
In vitro
Comparator
MOTS-c
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
In vitro experiments revealed the longer half-life of MP than MOTS-c, and in vivo experiments showed that oral administration of MP significantly ameliorated DSS-induced colitis.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of this study was to investigate the protective effects of MOTS-c against dextran sulfate sodium (DSS)-induced colitis.
In this study, MOTS-c was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MOTS-c.
Report a problemFND-3652807114

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 18:17 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.